Kb Financial Partners, LLC Argenx Se Transaction History

Kb Financial Partners, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$360.14 - $422.58 $6,122 - $7,183	-17 Reduced 42.5%	23 $9,000
Q4 2022 Feb 17, 2023	SELL	$342.17 - $402.31 $15,397 - $18,103	-45 Reduced 52.94%	40 $15,000
Q1 2022 May 17, 2022	BUY	$254.45 - $351.06 $11,450 - $15,797	45 Added 112.5%	85 $27,000
Q4 2021 Feb 18, 2022	BUY	$272.01 - $353.03 $10,880 - $14,121	40 New	40 $14,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Kb Financial Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Kb Financial Partners, LLC with notifications on news.